IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 317 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,945,782 | +29.9% | 109,034 | +17.5% | 0.00% | +100.0% |
Q2 2023 | $3,808,610 | +5.6% | 92,825 | -8.0% | 0.00% | 0.0% |
Q1 2023 | $3,607,810 | -40.8% | 100,946 | -37.5% | 0.00% | -50.0% |
Q4 2022 | $6,098,760 | +124.9% | 161,471 | +163.4% | 0.00% | +100.0% |
Q3 2022 | $2,712,000 | -57.0% | 61,310 | -64.0% | 0.00% | -66.7% |
Q2 2022 | $6,300,000 | -15.5% | 170,167 | -15.4% | 0.00% | +50.0% |
Q1 2022 | $7,453,000 | +26.5% | 201,201 | +3.9% | 0.00% | 0.0% |
Q4 2021 | $5,891,000 | +32.2% | 193,589 | +45.8% | 0.00% | +100.0% |
Q3 2021 | $4,455,000 | -28.0% | 132,812 | -14.4% | 0.00% | -50.0% |
Q2 2021 | $6,188,000 | +373.5% | 155,129 | +433.8% | 0.00% | – |
Q1 2021 | $1,307,000 | -68.0% | 29,062 | -59.8% | 0.00% | -100.0% |
Q4 2020 | $4,090,000 | -20.9% | 72,320 | -33.6% | 0.00% | -50.0% |
Q3 2020 | $5,169,000 | +79.9% | 108,928 | +123.4% | 0.00% | +100.0% |
Q2 2020 | $2,874,000 | -33.3% | 48,759 | -46.5% | 0.00% | -50.0% |
Q1 2020 | $4,308,000 | -52.0% | 91,103 | -38.6% | 0.00% | -33.3% |
Q4 2019 | $8,970,000 | -34.7% | 148,470 | -35.2% | 0.00% | -40.0% |
Q3 2019 | $13,727,000 | +46.8% | 229,125 | +57.5% | 0.01% | +25.0% |
Q2 2019 | $9,349,000 | +10.0% | 145,479 | +39.0% | 0.00% | 0.0% |
Q1 2019 | $8,496,000 | -9.0% | 104,662 | -39.4% | 0.00% | 0.0% |
Q4 2018 | $9,338,000 | +75.3% | 172,738 | +67.3% | 0.00% | +100.0% |
Q3 2018 | $5,327,000 | +63.0% | 103,264 | +31.7% | 0.00% | +100.0% |
Q2 2018 | $3,268,000 | -59.2% | 78,423 | -56.8% | 0.00% | -66.7% |
Q1 2018 | $8,003,000 | +76.1% | 181,556 | +100.9% | 0.00% | +50.0% |
Q4 2017 | $4,545,000 | -25.7% | 90,369 | -25.1% | 0.00% | -33.3% |
Q3 2017 | $6,117,000 | +76.9% | 120,646 | +77.5% | 0.00% | +50.0% |
Q2 2017 | $3,457,000 | -19.6% | 67,965 | -36.5% | 0.00% | 0.0% |
Q1 2017 | $4,302,000 | -29.8% | 107,004 | -16.4% | 0.00% | -33.3% |
Q4 2016 | $6,125,000 | +6.0% | 128,043 | -18.8% | 0.00% | 0.0% |
Q3 2016 | $5,781,000 | -27.7% | 157,781 | -54.0% | 0.00% | -40.0% |
Q2 2016 | $7,991,000 | +130.2% | 343,132 | +300.4% | 0.01% | +150.0% |
Q1 2016 | $3,471,000 | -69.2% | 85,705 | -52.9% | 0.00% | -71.4% |
Q4 2015 | $11,260,000 | – | 181,821 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |